"Myeloma Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Abnormal immunoglobulins characteristic of MULTIPLE MYELOMA.
| Descriptor ID |
D009194
|
| MeSH Number(s) |
D12.776.124.486.485.900.500 D12.776.124.790.651.900.500 D12.776.377.715.548.900.500 D12.776.624.553
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Myeloma Proteins".
Below are MeSH descriptors whose meaning is more specific than "Myeloma Proteins".
This graph shows the total number of publications written about "Myeloma Proteins" by people in this website by year, and whether "Myeloma Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myeloma Proteins" by people in Profiles.
-
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 02; 15(2):230-269.
-
Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2016 Jan; 16(1):36-42.
-
Oligosecretory biclonal multiple myeloma. J La State Med Soc. 2013 Jul-Aug; 165(4):215, 217-8.
-
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression. Cancer. 2011 Aug 15; 117(16):3758-62.
-
Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2004 May; 125(4):470-6.
-
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003 Jun; 121(5):749-57.
-
Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer. 2002 Mar 01; 94(5):1532-7.
-
IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity. 2001 Mar; 14(3):277-89.
-
Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol. 1999 Sep; 52(3):245-9.
-
Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys. 1998 Jul 15; 41(5):1063-7.